While the Zika virus is primarily transmitted by mosquitoes, research has shown that the disease can affect semen and sperm and can therefore be spread through sexual intercourse.
Wistar announces the appointment of Brian Keith, Ph.D., as Dean of Biomedical Studies. This new, strategic position will further Wistar’s educational mission to train scientists and continue priming workforce development programs and opportunities.
Wistar is pleased to announce the appointment of world-renowned scientist, medical oncologist and National Academy of Medicine member Chi Van Dang, M.D., Ph.D., as professor.
Wistar's Biomedical Research Technician (BRT) Apprenticeship has become the first-ever registered, nontraditional apprenticeship program in biomedical research approved by the Pennsylvania Department of Labor & Industry.
The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious diseases, announces the appointment of Daniel W. Kulp, Ph.D., as associate professor in the Vaccine Center and the Translational Tumor Immunology Program.
Scientists at The Wistar Institute have unveiled part of the protein complex that protects telomeres—the ends of our chromosomes.
Antibiotic-resistant strains of bacteria like Mycobacterium tuberculosis and Staphylococcus and pathogens like malaria are emerging throughout the world. Dotiwala’s research centers on the mechanisms of killer immune cells—such as natural killer and CD8 T cells—and how they target and destroy pathogens in host cells. This research could result in promising therapeutic strategies against infections that were once thought to be drug-resistant.
The Wistar Institute announces the appointment of Mohamed Abdel-Mohsen, Ph.D., as assistant professor in Wistar’s Vaccine Center.
Wistar scientists have secured more than $4,720,000 million in research funds.
The Wistar Institute, together with many regional academic institutions driving life sciences discoveries, has launched the Philadelphia Research Consortium – a preclinical research network for facilitating easy access to our region’s robust research enterprise.
Scientists at The Wistar Institute in collaboration with Roswell Park Cancer Institute found a significant association between a rare genetic variant of the p53 gene present in African American women and their risk of developing breast cancer in premenopausal age.
Scientists at The Wistar Institute and Inovio Pharmaceuticals, Inc. have devised a novel DNA vaccine approach through molecular design to improve the immune responses elicited against one of the most important cancer antigen targets.
Wistar scientists have shown an anti-diabetic drug can inhibit the growth of melanoma in older patients by activating an anti-aging gene that in turn inhibits a protein involved in metastatic progression and resistance to targeted therapies for the disease.
University of Pennsylvania and Wistar scientists have studied the physical feedback mechanisms between cancer cells and their environment and described how this interplay allows the migration and invasion of tumor cells.
Wistar announces the appointment of Joseph M. Salvino, Ph.D., as professor in the Molecular and Cellular Oncogenesis Program and Scientific Director of the Institute’s Molecular Screening Facility.
Wistar Scientists identified a novel protein pathway across several types of cancer that controls how tumor cells acquire the energy necessary for movement, invasion and metastasis.
Wistar welcomes Kenneth W. Hance, Ph.D., M.P.H., Director of Antibody Therapies, Immuno-Oncology & Combinations DPU at GlaxoSmithKline (GSK), as its first Visiting Professor from GSK at Wistar.
The Bill & Melinda Gates Foundation has awarded an $8,777,578 million grant to The Wistar Institute to create a preventative Zika therapy utilizing synthetic DNA monoclonal antibodies (dMAbs).
The Wistar Institute and Man’s Best Friend Therapeutics are pleased to announce a new collaboration that leverages Wistar’s groundbreaking vaccine research and development with MBFT’s expertise in developing animal health products.
In this preclinical study, 100 percent of the animal models were protected from Zika after vaccination followed by a challenge with the Zika virus. In addition, they were protected from degeneration in the cerebral cortex and hippocampal areas of the brain, while the other cohort showed degeneration of the brain after Zika infection.
Scientists at The Wistar Institute have demonstrated how a protein called TRAP1 – an important regulator of energy production in healthy and cancerous cells – is an important driver of prostate cancer and appears to be a valuable therapeutic target for the disease.
Researchers at The Wistar Institute have identified a protein that plays a critical role in the expression of cytokines and chemokines, and that decreasing this protein suppresses the expression of these secreted factors. This suggests that there may be ways of promoting the positive effects of senescence while suppressing its negative effects.
New research from The Wistar Institute showed that estrogen signaling was responsible for immunosuppressive effects in the tumor microenvironment across cancer types. These findings pave the way for combining immunotherapeutic treatments with anti-estrogen drugs that may significantly extend survival.
Two Philadelphia research institutions are marking the 10th anniversary of a vaccine against rotavirus.
Wistar scientists have received nearly $1
New research from The Wistar Institute demonstrates how a drug already in clinical trials could be used to boost anti-tumor immunity and cause T-cells to target the cancer directly while minimizing side effects.
Wistar is pleased to announce that Ashani Weeraratna, Ph.D., associate professor and program leader in the Tumor Microenvironment and Metastasis Program, has been named the Ira Brind Associate Professor.
New research from The Wistar Institute demonstrates how two key proteins mediate the organization of chromosomes and our genome, shedding light on one of the key genetic processes for every person. With this key basic information in hand, scientists may now be able to pinpoint the origins of cancer due to genetic mutations.
Wistar has been awarded a Nontraditional Apprenticeship Grant by the Pa. Dept. of Labor & Industry to explore implementing the Biomedical Technician Training Program for the Pa. region.
Wistar scientists have identified a novel mechanism that selectively operates in hypoxic tumors to enable tumor cells to thrive and continue to proliferate despite a low oxygen environment. Dario C. Altieri, M.D., Wistar’s President and CEO and lead author of the study, and colleagues showed how the activation of this pathway leads to an unfavorable prognosis for patients with gliomas – a type of brain tumor – and how the pathway could be a valuable therapeutic target in cancer.
Wistar scientists have identified a marker that distinguishes PMN-MDSCs from neutrophils in the blood of patients with a variety of cancers.
Scientists at The Wistar Institute have discovered a receptor-protein that is expressed on the surface of different types of ovarian tumor cells, including clear cell and mucinous ovarian tumors, two of the most aggressive subtypes of the disease. The protein is not found on non-ovarian healthy tissues in adult women, meaning that this protein could represent a highly specific therapeutic target in a range of ovarian tumors. Additionally, T-cells could be directed to treat these tumors with almost no adverse effects observed.
NIH awards Wistar and partners nearly $23M grant for HIV cure research
Scientists at The Wistar Institute have identified a specific network of proteins present in mitochondria of tumor cells that is essential for maintaining a clean function of mitochondria, enabling not only the proliferation of tumor cells but also their ability to move and invade distant organs. By understanding the players involved, Wistar scientists were able to turn off individual subunits within the network, which greatly reduced the ability of cancer cells to grow and spread, suggesting an attractive new therapeutic target.
Jeff Fahnoe appointed Wistar Chief Information Officer
Susan B. Dillon, Ph.D., is appointed to Wistar's Board of Trustees
The U.S. Food and Drug Administration has approved initiation of the first phase I human trial for a Zika vaccine, based on new research with key findings generated in the lab of David B. Weiner, Ph.D., executive vice president, director of the Vaccine Center, and the W.W. Smith Endowed Chair in Cancer Research at The Wistar Institute.
Wistar is part of global, women-led team awarded MRA grant to fund collaborative melanoma research
Latest Wistar Institute funding received
Immunotherapy advances apply to animal health
Wistar announces David B. Weiner has been appointed to the W.W. Smith Charitable Trust Professorship in Cancer Research
Global collaboration applies Wistar expertise to promising Cormorant therapeutic drug development
Wistar appoints Jennifer Evans Stacey, Esq., as Vice President, General Counsel, Secretary and Government Relations
Wistar appoints Zachary Schug, Ph.D., as Assistant Professor
An international team of scientists led by The Wistar Institute have shown that aged tumor cells in melanoma behave differently than younger tumor cells, according to study results published in the journal Nature. Changes in the microenvironment make these older tumor cells more metastatic and more resistant to treatment with targeted therapies.
Wistar announces the appointment of Kavitha Sarma, Ph.D., as assistant professor in Wistar’s Gene Expression and Regulation Program.
Now, new research from The Wistar Institute has demonstrated how a novel vaccine strategy that boosts the immune system by rapidly producing antibodies against CHIKV, combined with a traditional DNA-based vaccine approach, can provide both short term and long term protection against the virus. Study results are published in the Journal of Infectious Diseases.
New research from The Wistar Institute has pinpointed a single variant in a gene that is only found in Africans and African Americans, which makes cancer resistant to cell death and may contribute to increased cancer risk.
Wistar appoints new Board of Trustees member
New research from The Wistar Institute demonstrated that dozens of these targeted therapies suppressed the activity of T cells that could actually help fight tumors. While studying the FDA-approved targeted therapy trametinib, the researchers also found that pairing it with a signaling protein “superagonist” stimulated T cell activity while preserving the cancer-blocking effects of the cancer treatment.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right